Stifel analyst Jonathan Block added Sientra (SIEN) to the firm's Select List, replacing IntriCon (IIN). His survey of 70 dermatologists, 48 plastic surgeons and 25 other doctors "paints a bullish picture" for adoption of Sientra's miraDry over the next 12-24 months, Block tells investors. The overall shift to non-invasive procedures is expected to continue and it appears that miraDry will play a central role, Block added. He keeps a Buy rating on Sientra shares, though he lowered his price target on the stock to $19 from $24. He also cut his price target on Cutera (CUTR) to $17 from $29 and lowered his price target on Viveve (VIVE) to $3 from $5 following his survey work. Block keeps a Hold rating on Cutera and Buy rating on Viveve.